Menu
Dividend AristocratsDividend KingsHigh YieldMonthly DividendDividend CalendarScreener

Bristol-Myers Squibb Company Stock Price History

Bristol-Myers Squibb Company EPS

EPSDividend / share
-5.2-2.40.53.36.12007200920112013201520172019202120232025

Bristol-Myers Squibb Company Dividend per Share

Forward Yield
4.41%
Annual Dividend
2.52 USD
Payout
70.03%
Frequency
Quarterly
Yrs of growth
4
CAGR 5Y
-9.52%
0.01.12.23.34.4197219771982198719921997200220072012201720222025

Bristol-Myers Squibb Company Dividend Yield

Bristol-Myers Squibb Company Payout Ratio

0%138%276%414%552%200720092011201320152017201920222025

Bristol-Myers Squibb Company Dividend Growth

1Y CAGR
3Y CAGR
5Y CAGR
10Y CAGR
20Y CAGR
3.33%
4.71%
-9.52%
-1.82%
4.05%
Compound annual growth rate of dividend per share
Yield vs sector
4.41%
avg Healthcare: 2.97%
Next ex-dividend (est.)
2026-07-02
last: 2026-04-02
Ex-DateAmount
2026-04-020.63 USD
2026-01-020.63 USD
2025-10-030.62 USD
2025-07-030.62 USD
2025-04-040.62 USD
2025-01-030.62 USD
2024-10-040.60 USD
2024-07-050.60 USD

Bristol-Myers Squibb Company is a global biopharmaceutical company headquartered in Princeton, New Jersey, and founded in 1933. It discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines addressing serious diseases worldwide. The company offers a diverse portfolio including small molecule drugs, biologics produced from biological processes, and advanced chimeric antigen receptor (CAR-T) cell therapies. Key therapeutic areas encompass oncology with treatments like nivolumab (Opdivo) and ipilimumab (Yervoy), hematology featuring lenalidomide (Revlimid) and luspatercept (Reblozyl), immunology such as abatacept (Orencia), cardiovascular including apixaban (Eliquis), neuroscience, and other immunology and fibrosis-related conditions. Bristol-Myers Squibb Company plays a vital role in the healthcare sector by providing therapies for cancer, immune disorders, cardiovascular diseases, and beyond, serving patients through collaborations and a focus on unmet medical needs in these critical markets.